Il Han Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Il Han Song has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Suk Bae Kim
Division of Hepatology, Department of Internal Medicine, Dankook University College of Medicine, Dankook University Hospital, 201 Manghyang-ro, Dongnam-gu, Cheonan, Chungcheongnam-do 31116, Republic of Korea
16 shared publicationsHa Yan Kang
Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea
10 shared publicationsHyun Deok Shin
10 shared publicationsHong Ja Kim
Division of Gastroenterology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea (the Republic of)
7 shared publicationsJeong Eun Shin
7 shared publicationsSe Young Yun
6 shared publications
Latest Publications
- Open Access
- 30 April 2025
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 14  (2) , 77-80
Endovascular intervention for portal vein system thrombosis in a patient with protein S deficiency: A case report
Min Jeong Choi and Il Han Song. Int J Gastrointest Interv 2025;14:77-80. https://doi.org/10.18528/ijgii240068
- 30 April 2025
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 14  (2) , 77-80
Open AccessEndovascular intervention for portal vein system thrombosis in a patient with protein S deficiency: A case report
Min Jeong Choi and Il Han Song. Int J Gastrointest Interv 2025;14:77-80. https://doi.org/10.18528/ijgii240068
- Open Access
- 31 July 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42  (4) , 531-533
Antineutrophil cytoplasmic antibody-associated vasculitis presenting as kidney rupture and gonadal artery hemorrhage
A 70-year-old man was transferred to our department of nephrology for the evaluation of persistent fever and azotemia. He has been treated with anti-tuberculous (Tb) medication for Tb pleurisy in recent weeks. The laboratory findings at transfer were as follows: white blood cells, 25,030/mm 3 ; hemoglobin, 11.8 g/dL; platelets, 545,000/ mm 3 ; C-reactive protein, 13 mg/dL; protein/albumin, 6.1/2.6 g/dL; blood urea nitrogen, 28 mg/dL; and creatinine, 2.06 mg/dL. Urinalysis showed both proteinuria (4+) and hematuria (4+). Serologic markers including immunoglobulin and complements were within normal range, except that myeloperoxidase anti-neutrophil cytoplasmic antibody (ANCA) was positive. On suspicion of ANCA vasculitis, 500-mg methylprednisolone was administered. While planning renal biopsy, the patient complained of severe right flank pain, and his hemoglobin level decreased from 11 to 7 g/dL. Abdominopelvic computed tomography showed kidney rupture with a subcapsular hematoma, and renal angiography revealed innumerous punctate contrast staining and a minute leak in the vascular bed of right renal artery (Fig. 1); total embolization of the right renal artery
- 31 July 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42  (4) , 531-533
Open AccessAntineutrophil cytoplasmic antibody-associated vasculitis presenting as kidney rupture and gonadal artery hemorrhage
A 70-year-old man was transferred to our department of nephrology for the evaluation of persistent fever and azotemia. He has been treated with anti-tuberculous (Tb) medication for Tb pleurisy in recent weeks. The laboratory findings at transfer were as follows: white blood cells, 25,030/mm 3 ; hemoglobin, 11.8 g/dL; platelets, 545,000/ mm 3 ; C-reactive protein, 13 mg/dL; protein/albumin, 6.1/2.6 g/dL; blood urea nitrogen, 28 mg/dL; and creatinine, 2.06 mg/dL. Urinalysis showed both proteinuria (4+) and hematuria (4+). Serologic markers including immunoglobulin and complements were within normal range, except that myeloperoxidase anti-neutrophil cytoplasmic antibody (ANCA) was positive. On suspicion of ANCA vasculitis, 500-mg methylprednisolone was administered. While planning renal biopsy, the patient complained of severe right flank pain, and his hemoglobin level decreased from 11 to 7 g/dL. Abdominopelvic computed tomography showed kidney rupture with a subcapsular hematoma, and renal angiography revealed innumerous punctate contrast staining and a minute leak in the vascular bed of right renal artery (Fig. 1); total embolization of the right renal artery
- Open Access
- 1 November 2020
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 35  (6) , 1305-1316
The clinical impact of gut microbiota in chronic kidney disease
Gut microorganisms play critical roles in both maintaining host homeostasis and the development of diverse diseases. Gut dysbiosis, an alteration of the composition and function of gut microorganisms, is commonly seen in patients with chronic kidney disease (CKD). CKD itself contributes to a disruption of the symbiotic relationship between the gut microbiota and the host, while the resulting gut dysbiosis may play a part in stage progression of CKD. This bidirectional relationship supports the concept that the gut microbiota is considered a novel focus for the pathogenesis and management of CKD. This article examines the interaction between the gut microbiota and the kidney, the mutual effects of dysbiosis and CKD, and possible treatment options to restore gut eubiosis, and reduce CKD progression and its related complications.
- 1 November 2020
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 35  (6) , 1305-1316
Open AccessThe clinical impact of gut microbiota in chronic kidney disease
Gut microorganisms play critical roles in both maintaining host homeostasis and the development of diverse diseases. Gut dysbiosis, an alteration of the composition and function of gut microorganisms, is commonly seen in patients with chronic kidney disease (CKD). CKD itself contributes to a disruption of the symbiotic relationship between the gut microbiota and the host, while the resulting gut dysbiosis may play a part in stage progression of CKD. This bidirectional relationship supports the concept that the gut microbiota is considered a novel focus for the pathogenesis and management of CKD. This article examines the interaction between the gut microbiota and the kidney, the mutual effects of dysbiosis and CKD, and possible treatment options to restore gut eubiosis, and reduce CKD progression and its related complications.
- Open Access
- 4 June 2020
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2020, 1-9
Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Background. Nonalcoholic fatty liver disease (NAFLD) may develop into liver cirrhosis and hepatocellular carcinoma (HCC). The aim of this study was to compare the clinical patterns and survival outcomes of NAFLD-related HCC patients and those of alcoholic liver disease (ALD)-related or hepatitis B virus (HBV)-related HCC patients. Methods. A total of 622 HCC patients with associated NAFLD (n = 56), ALD (n = 173), or HBV infection (n = 393) were enrolled. The clinical characteristics and survival were analyzed according to the underlying liver diseases. Results. NAFLD-related HCC patients were more commonly older women and had more metabolic risk factors but were less likely to have cirrhosis and ascites, compared to ALD-related or HBV-related HCC patients. NAFLD-related HCC more often had an infiltrative pattern (), a larger tumor (), more macrovascular invasion (), and exceeded the Milan criteria (), but was less frequently diagnosed during tumor surveillance (). Survival analysis did not show any difference among NAFLD-related, ALD-related, and HBV-related HCC patients. Furthermore, propensity score matching analysis did not reveal a significant difference in the median survival between the different groups (NAFLD vs. ALD, 14.0 months [95% confidence interval (CI), 2.0–26.0] vs. 13.0 months [95% CI, 0–26.3]; , NAFLD vs. HBV, 14.0 months [95% CI, 2.0–26.0] vs. 12.0 months [95% CI, 4.3–17.8]; ). Conclusions. NAFLD-related HCCs were more often detected at an advanced stage with infiltrative patterns, although they showed no significant difference in survival compared to ALD-related or HBV-related HCCs. A future prospective research should be focused on identifying NAFLD patients who require strict surveillance in order to early detect and timely treat HCC.- 4 June 2020
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2020, 1-9
Open AccessClinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Background. Nonalcoholic fatty liver disease (NAFLD) may develop into liver cirrhosis and hepatocellular carcinoma (HCC). The aim of this study was to compare the clinical patterns and survival outcomes of NAFLD-related HCC patients and those of alcoholic liver disease (ALD)-related or hepatitis B virus (HBV)-related HCC patients. Methods. A total of 622 HCC patients with associated NAFLD (n = 56), ALD (n = 173), or HBV infection (n = 393) were enrolled. The clinical characteristics and survival were analyzed according to the underlying liver diseases. Results. NAFLD-related HCC patients were more commonly older women and had more metabolic risk factors but were less likely to have cirrhosis and ascites, compared to ALD-related or HBV-related HCC patients. NAFLD-related HCC more often had an infiltrative pattern (), a larger tumor (), more macrovascular invasion (), and exceeded the Milan criteria (), but was less frequently diagnosed during tumor surveillance (). Survival analysis did not show any difference among NAFLD-related, ALD-related, and HBV-related HCC patients. Furthermore, propensity score matching analysis did not reveal a significant difference in the median survival between the different groups (NAFLD vs. ALD, 14.0 months [95% confidence interval (CI), 2.0–26.0] vs. 13.0 months [95% CI, 0–26.3]; , NAFLD vs. HBV, 14.0 months [95% CI, 2.0–26.0] vs. 12.0 months [95% CI, 4.3–17.8]; ). Conclusions. NAFLD-related HCCs were more often detected at an advanced stage with infiltrative patterns, although they showed no significant difference in survival compared to ALD-related or HBV-related HCCs. A future prospective research should be focused on identifying NAFLD patients who require strict surveillance in order to early detect and timely treat HCC. - Open Access
- 1 January 2020
- Published by Taylor & Francis in Medical Education Online
- Vol. 25  (1)
Perception and attitudes of medical students on clinical clerkship in the era of the Coronavirus Disease 2019 pandemic
The Coronavirus Disease 2019 (COVID-19) has been placing severe strain on global healthcare systems and medical education programs, leading to growing demands for medical students to assume the rol...
- 1 January 2020
- Published by Taylor & Francis in Medical Education Online
- Vol. 25  (1)
Open AccessPerception and attitudes of medical students on clinical clerkship in the era of the Coronavirus Disease 2019 pandemic
The Coronavirus Disease 2019 (COVID-19) has been placing severe strain on global healthcare systems and medical education programs, leading to growing demands for medical students to assume the rol...
- Open Access
- 1 July 2018
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 33  (4) , 670-678
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
Hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is associated with increased liver-related morbidity and mortality rates, accelerated progression to end-stage renal disease, and risk of cardiovascular events. CKD patients with HCV infection require antiviral therapy. Pegylated interferon (peg-IFN) plus ribavirin was the standard of care for HCV-infected CKD patients before the introduction of first-generation direct-acting antiviral (DAA) oral anti-HCV agents. Peg-IFN-based treatment has a low virologic response rate and poor compliance, resulting in a high dropout rate. Recently, several clinical trials of all-DAA combination regimens have reported excellent antiviral efficacy and few adverse drug reactions in HCV-infected patients with CKD. These positive results have revolutionized the treatment of chronic HCV infection in this population. In this review, we address the impact of chronic HCV infection in CKD patients, and discuss their management using next-generation DAAs.
- 1 July 2018
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 33  (4) , 670-678
Open AccessHepatitis C virus infection in chronic kidney disease: paradigm shift in management
Hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is associated with increased liver-related morbidity and mortality rates, accelerated progression to end-stage renal disease, and risk of cardiovascular events. CKD patients with HCV infection require antiviral therapy. Pegylated interferon (peg-IFN) plus ribavirin was the standard of care for HCV-infected CKD patients before the introduction of first-generation direct-acting antiviral (DAA) oral anti-HCV agents. Peg-IFN-based treatment has a low virologic response rate and poor compliance, resulting in a high dropout rate. Recently, several clinical trials of all-DAA combination regimens have reported excellent antiviral efficacy and few adverse drug reactions in HCV-infected patients with CKD. These positive results have revolutionized the treatment of chronic HCV infection in this population. In this review, we address the impact of chronic HCV infection in CKD patients, and discuss their management using next-generation DAAs.
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33  (42) , e264
Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study
Kim SE, et al. J Korean Med Sci. 2018 Sep;33(42):e264. https://doi.org/10.3346/jkms.2018.33.e264
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33  (42) , e264
Open AccessChronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study
Kim SE, et al. J Korean Med Sci. 2018 Sep;33(42):e264. https://doi.org/10.3346/jkms.2018.33.e264
- Open Access
- 4 April 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17  (1) , 1-19
Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis
The long-term clinical outcomes of antiviral therapy for patients with chronic hepatitis C are uncertain in terms of hepatitis C virus (HCV)-related morbidity and mortality according to the response to antiviral therapy. This study aimed to assess the impact of antiviral treatment on the development of HCC and mortality in patients with chronic HCV infection. A systematic review was conducted for studies that evaluated the antiviral efficacy for patients with chronic hepatitis C or assessed the development of HCC or mortality between SVR (sustained virologic response) and non-SVR patients. The methodological quality of the enrolled publications was evaluated using Risk of Bias table or Newcastle-Ottawa scale. Random-effect model meta-analyses and meta-regression were performed. Publication bias was assessed. In total, 59 studies (4 RCTs, 15 prospective and 40 retrospective cohort studies) were included. Antiviral treatment was associated with reduced development of HCC (vs. no treatment; OR 0.392, 95% CI 0.275–0.557), and this effect was intensified when SVR was achieved (vs. no SVR, OR: 0.203, 95% CI 0.164–0.251). Antiviral treatment was associated with lower all-cause mortality (vs. no treatment; OR 0.380, 95% CI 0.295–0.489) and liver-specific mortality (OR 0.363, 95% CI 0.260–0.508). This rate was also intensified when SVR was achieved [all-cause mortality (vs. no SVR, OR 0.255, 95% CI 0.199–0.326), liver-specific mortality (OR 0.126, 95% CI 0.094–0.169)]. Sensitivity analyses revealed robust results, and a small study effect was minimal. In patients with chronic hepatitis C, antiviral therapy can reduce the development of HCC and mortality, especially when SVR is achieved.
- 4 April 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17  (1) , 1-19
Open AccessImpact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis
The long-term clinical outcomes of antiviral therapy for patients with chronic hepatitis C are uncertain in terms of hepatitis C virus (HCV)-related morbidity and mortality according to the response to antiviral therapy. This study aimed to assess the impact of antiviral treatment on the development of HCC and mortality in patients with chronic HCV infection. A systematic review was conducted for studies that evaluated the antiviral efficacy for patients with chronic hepatitis C or assessed the development of HCC or mortality between SVR (sustained virologic response) and non-SVR patients. The methodological quality of the enrolled publications was evaluated using Risk of Bias table or Newcastle-Ottawa scale. Random-effect model meta-analyses and meta-regression were performed. Publication bias was assessed. In total, 59 studies (4 RCTs, 15 prospective and 40 retrospective cohort studies) were included. Antiviral treatment was associated with reduced development of HCC (vs. no treatment; OR 0.392, 95% CI 0.275–0.557), and this effect was intensified when SVR was achieved (vs. no SVR, OR: 0.203, 95% CI 0.164–0.251). Antiviral treatment was associated with lower all-cause mortality (vs. no treatment; OR 0.380, 95% CI 0.295–0.489) and liver-specific mortality (OR 0.363, 95% CI 0.260–0.508). This rate was also intensified when SVR was achieved [all-cause mortality (vs. no SVR, OR 0.255, 95% CI 0.199–0.326), liver-specific mortality (OR 0.126, 95% CI 0.094–0.169)]. Sensitivity analyses revealed robust results, and a small study effect was minimal. In patients with chronic hepatitis C, antiviral therapy can reduce the development of HCC and mortality, especially when SVR is achieved.
- Open Access
- 1 January 2017
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 69  (5) , 298-307
The Performance of Serum Biomarkers for Predicting Fibrosis in Patients with Chronic Viral Hepatitis
Bang CS, et al. Korean J Gastroenterol. 2017 May;69(5):298-307. https://doi.org/10.4166/kjg.2017.69.5.298
- 1 January 2017
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 69  (5) , 298-307
Open AccessThe Performance of Serum Biomarkers for Predicting Fibrosis in Patients with Chronic Viral Hepatitis
Bang CS, et al. Korean J Gastroenterol. 2017 May;69(5):298-307. https://doi.org/10.4166/kjg.2017.69.5.298
- Open Access
- 30 August 2016
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2016, 1-8
Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection
Aim. This study aimed to assess clinical impact of hepatitis C viral load on the development of hepatocellular carcinoma (HCC) and liver-related mortality in HCV-infected patients.Methods. A total of 111 subjects with chronic HCV infection who were available for serum quantitation of HCV RNA were recruited in this retrospective cohort. Cox-proportional hazards models were used to calculate hazard ratio (HR) of developing HCC and liver-related mortality according to serum HCV RNA titers.Results. HCC was developed in 14 patients during follow-up period. The cumulative risk of HCC development was higher in subjects with high HCV RNA titer (log HCV RNA IU/mL > 6) than subjects with low titer (log HCV RNA IU/mL ≦ 6) (HR = 4.63,), giving an incidence rate of 474.1 and 111.5 per 10,000 person-years, respectively. Old age (HR = 9.71,), accompanying cirrhosis (HR = 19.34,), and low platelet count (HR = 13.97,) were other independent risk factors for the development of HCC. Liver-related death occurred in 7 patients. Accompanying cirrhosis (HR = 6.13,) and low albumin level (HR = 9.17,), but not HCV RNA titer, were significant risk factors related to liver-related mortality.Conclusion. Serum HCV RNA titer may be considered an independent risk factor for the development of HCC but not liver-related mortality.- 30 August 2016
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2016, 1-8
Open AccessClinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection
Aim. This study aimed to assess clinical impact of hepatitis C viral load on the development of hepatocellular carcinoma (HCC) and liver-related mortality in HCV-infected patients.Methods. A total of 111 subjects with chronic HCV infection who were available for serum quantitation of HCV RNA were recruited in this retrospective cohort. Cox-proportional hazards models were used to calculate hazard ratio (HR) of developing HCC and liver-related mortality according to serum HCV RNA titers.Results. HCC was developed in 14 patients during follow-up period. The cumulative risk of HCC development was higher in subjects with high HCV RNA titer (log HCV RNA IU/mL > 6) than subjects with low titer (log HCV RNA IU/mL ≦ 6) (HR = 4.63,), giving an incidence rate of 474.1 and 111.5 per 10,000 person-years, respectively. Old age (HR = 9.71,), accompanying cirrhosis (HR = 19.34,), and low platelet count (HR = 13.97,) were other independent risk factors for the development of HCC. Liver-related death occurred in 7 patients. Accompanying cirrhosis (HR = 6.13,) and low albumin level (HR = 9.17,), but not HCV RNA titer, were significant risk factors related to liver-related mortality.Conclusion. Serum HCV RNA titer may be considered an independent risk factor for the development of HCC but not liver-related mortality.